ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
ProKidney (Nasdaq: PROK) will present two posters at the American Society of Nephrology Kidney Week 2025 in Houston, Nov 6–9, 2025. One is a late‑breaking poster reporting Phase 2 REGEN‑007 study results: "Renal Autologous Cell Therapy in Diabetes and CKD" (Session: Late‑Breaking Science Posters, Nov 6, 10:00 AM–12:00 PM CST, Board #TH‑PO1203). The second poster covers the inflammatory profile of the cell therapy candidate rilparencel (Session: Development, Stem Cells, and Regenerative Medicine, Nov 6, 10:00 AM–12:00 PM CST, Board #TH‑PO0575).
Copies of both posters will be available on the company website after the event and abstracts are listed on the ASN Kidney Week program site.
ProKidney (Nasdaq: PROK) presenterà due poster all'American Society of Nephrology Kidney Week 2025 a Houston, dal 6 al 9 novembre 2025. Uno è un poster dell'ultima ora che riporta i risultati dello studio di fase 2 REGEN-007: "Renal Autologous Cell Therapy in Diabetes and CKD" (Session: Late-Breaking Science Posters, 6 novembre, 10:00–12:00 CST, Board #TH-PO1203). Il secondo poster riguarda il profilo infiammatorio del candidato alla terapia cellulare rilparencel (Session: Development, Stem Cells, and Regenerative Medicine, 6 novembre, 10:00–12:00 CST, Board #TH-PO0575).
Le copie di entrambi i poster saranno disponibili sul sito dell'azienda dopo l'evento e gli abstract saranno elencati sul sito del programma ASN Kidney Week.
ProKidney (Nasdaq: PROK) presentará dos carteles en la American Society of Nephrology Kidney Week 2025 en Houston, del 6 al 9 de noviembre de 2025. Uno es un cartel de última hora que informa los resultados del estudio de Fase 2 REGEN-007: "Renal Autologous Cell Therapy in Diabetes and CKD" (Sesión: Late-Breaking Science Posters, 6 de noviembre, de 10:00 a.m. a 12:00 p.m. CST, Tarjeta #TH-PO1203). El segundo cartel cubre el perfil inflamatorio del candidato de terapia celular rilparencel (Sesión: Development, Stem Cells, and Regenerative Medicine, 6 de noviembre, de 10:00 a.m. a 12:00 p.m. CST, Tarjeta #TH-PO0575).
Copias de ambos carteles estarán disponibles en el sitio web de la empresa después del evento y los resúmenes se listarán en el sitio del programa ASN Kidney Week.
프로키드니(PROK) 주식회사는 2025년 11월 6일부터 9일까지 휴스턴에서 열리는 American Society of Nephrology Kidney Week 2025에서 포스터 두 편을 발표합니다. 하나는 마감 임박 포스터로 2상 REGEN-007 연구 결과를 보고합니다: "Renal Autologous Cell Therapy in Diabetes and CKD" (세션: Late-Breaking Science Posters, 11월 6일, 10:00–12:00 CST, Board #TH-PO1203). 두 번째 포스터는 세포 치료제 rilparencel의 염증 프로파일을 다룹니다 (세션: Development, Stem Cells, and Regenerative Medicine, 11월 6일, 10:00–12:00 CST, Board #TH-PO0575).
이벤트 후 두 포스터의 사본이 회사 웹사이트에 게시되며 초록은 ASN Kidney Week 프로그램 사이트에 목록으로 제공됩니다.
ProKidney (Nasdaq: PROK) présentera deux posters lors du Kidney Week 2025 de l'American Society of Nephrology à Houston, du 6 au 9 novembre 2025. L'un est un poster de dernière minute présentant les résultats de l'étude de phase 2 REGEN-007: "Renal Autologous Cell Therapy in Diabetes and CKD" (Séance: Late-Breaking Science Posters, 6 novembre, 10h00–12h00 CST, Board #TH-PO1203). Le deuxième poster couvre le profil inflammatoire du candidat à la thérapie cellulaire rilparencel (Séance: Development, Stem Cells, and Regenerative Medicine, 6 novembre, 10h00–12h00 CST, Board #TH-PO0575).
Des copies des deux posters seront disponibles sur le site Internet de l'entreprise après l'événement et les résumés seront listés sur le site du programme ASN Kidney Week.
ProKidney (Nasdaq: PROK) wird zwei Poster auf der American Society of Nephrology Kidney Week 2025 in Houston, vom 6. bis 9. November 2025, präsentieren. Eines ist ein late-breaking Poster, das Ergebnisse der Phase-2-Studie REGEN-007 berichtet: "Renal Autologous Cell Therapy in Diabetes and CKD" (Sitzung: Late-Breaking Science Posters, 6. November, 10:00–12:00 CST, Board #TH-PO1203). Der zweite Poster behandelt das inflammatorische Profil des Zelltherapie-Kandidaten rilparencel (Sitzung: Development, Stem Cells, and Regenerative Medicine, 6. November, 10:00–12:00 CST, Board #TH-PO0575).
Kopien beider Poster werden nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein und die Abstracts sind auf der ASN Kidney Week-Programmseite aufgeführt.
ProKidney (بورصة ناسداك: PROK) ستعرض اثنين من الملصقات في أسبوع الكلى 2025 لجمعية أمراض الكلى الأمريكية في هيوستن، من 6 إلى 9 نوفمبر 2025. أحدهما ملصق عاجل متأخر يعلن عن نتائج دراسة المرحلة 2 REGEN-007: "Renal Autologous Cell Therapy in Diabetes and CKD" (الجلسة: Late-Breaking Science Posters, 6 نوفمبر، 10:00 صباحاً–12:00 ظهراً بتوقيت CST، المجلس #TH-PO1203). الملصق الثاني يغطي الملف الالتهابي للمرشح العلاج الخلوي rilparencel (الجلسة: Development, Stem Cells, and Regenerative Medicine، 6 نوفمبر، 10:00 صباحاً–12:00 ظهراً بتوقيت CST، المجلس #TH-PO0575).
نسخ من كلا الملصقين ستكون متاحة على موقع الشركة الإلكتروني بعد الحدث وسيتم إدراج الملخصات في موقع برنامج ASN Kidney Week.
ProKidney (纳斯达克：PROK) 将在 2025 年美国肾脏学会 Kidney Week 于休斯顿举行，时间为 2025 年 11 月 6 日至 9 日，展示两个海报。一个是 晚期突破海报，报告 Phase 2 REGEN-007 研究结果：“Renal Autologous Cell Therapy in Diabetes and CKD”（会议：Late-Breaking Science Posters，11 月 6 日，CST 10:00–12:00，板块 #TH-PO1203）。第二个海报涵盖细胞治疗候选 rilparencel 的炎症特征（会议：Development, Stem Cells, and Regenerative Medicine，11 月 6 日，CST 10:00–12:00，板块 #TH-PO0575）。
两份海报的副本将在活动结束后在公司网站上提供，摘要将列在 ASN Kidney Week 项目网站上。
- None.
- None.
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX.
The titles for the accepted abstracts are provided below and accessible online at: https://www.asn-online.org/education/kidneyweek/2025/program-search-abstract.aspx
Late-Breaking Poster Presentation
Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results)
Session Title: Late-Breaking Science Posters [LB-PO]
Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST
Poster Board #: TH-PO1203
Other Poster Presentation
Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel
Session Title: Development, Stem Cells, and Regenerative Medicine [PO0600]
Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST
Poster Board #: TH-PO0575
Following the event, a copy of the poster presentations will be available on the Company’s website at: https://prokidney.com/our-technology/publications/
Additional information on ASN Kidney Week 2025 can be accessed online at:
https://www.asn-online.org/education/kidneyweek
About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.
ProKidney Contact
Ethan Holdaway
Ethan.Holdaway@prokidney.com
Media Contact
Audra Friis
audrafriis@sambrown.com
Investor Relations Contact
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When will ProKidney (PROK) present the Phase 2 REGEN-007 results at ASN Kidney Week 2025?
What is the title of ProKidney's late-breaking poster at ASN Kidney Week 2025?
When and where is ASN Kidney Week 2025 where PROK will present?
What other ProKidney poster will be presented and when is it scheduled?
Where can investors access ProKidney's poster presentations after ASN Kidney Week 2025?
Where can I find the ASN Kidney Week 2025 abstracts for ProKidney (PROK)?
